

ORIGINAL ARTICLE

Occupational cannabis exposure and allergy risks

Ine Ilona Decuyper,¹ Athina Van Gasse,¹ Margaretha Antje Faber,¹ Christel Mertens,¹ Jessy Elst,¹ Hans-Peter Rihs,² Vito Sabato,¹ Hilde Lapeere,³ Margo Hagendorens,¹ Chris Bridts,¹ Luc De Clerck,¹ Didier Ebo¹

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/oemed-2018-105302>).

¹Department of Immunology-Allergology-Rheumatology, University of Antwerp, Antwerp (Belgium) and Antwerp University Hospital, Antwerp, Belgium

²Institute for Prevention and Occupational Medicine, German Social Accident Insurance, Ruhr-University Bochum, Bochum, Belgium

³Ghent University Hospital, University of Ghent, Ghent, Germany

Correspondence to

Professor Didier Ebo, Department of Immunology-Allergology-Rheumatology, Faculty of Medicine and Health Sciences, Antwerp University, Antwerp 2610, Belgium; didier.ebo@uantwerpen.be

Received 18 June 2018

Revised 29 October 2018

Accepted 6 November 2018

ABSTRACT

Objectives Cannabis allergy has mainly been described following recreational use but some cases also point to cannabis sensitisation as a result of occupational exposure. As a consequence, little is known on the prevalence and clinical phenotype of occupational cannabis allergy. Therefore, this study aims to explore the allergy-associated health risks of occupational cannabis exposure in Belgian police force personnel.

Methods 81 participants, active in the police force, reporting regular occupational cannabis exposure during the past 12 months, were included. History was combined with a standardised questionnaire on allergies and cannabis exposure. Basophil activation tests (BATs) with a crude cannabis extract and rCan s 3 were performed. In addition, specific (s)IgE rCan s 3 as well as sIgE to house dust mite, six pollen and three mould allergens were quantified.

Results Although 42% of the participants reported respiratory and/or cutaneous symptoms on occupational cannabis exposure, all cannabis diagnostics were entirely negative, except one symptomatic case demonstrating a borderline result. Furthermore, there is no significant difference between the groups with and without symptoms on cannabis exposure in terms of allergenic sensitisations.

Conclusions The origins of the reported respiratory and cutaneous symptoms during cannabis exposure remain elusive but are probably due to non-immune reactions. It should be noted that the study was volunteer-based possibly reflecting an excessive number of symptomatic individuals. Nevertheless, as only one participant reported using fully protective gear, much improvement is needed for reducing the number of symptoms reported on duty, independent of their origin.

INTRODUCTION

Since the first report dating back to 1971,¹ IgE-mediated *Cannabis sativa* allergy has mainly been described in a setting of recreational (ab)use.^{2–9} However, some anecdotal case reports and small series also point to cannabis sensitisation and allergy in a context of occupational exposure.^{10–16} To date, cannabis allergy has been described in cannabis growers, bird breeders, factory workers and laboratory personnel reporting both cutaneous and/or respiratory symptoms on exposure. These reports show allergic reactivity to cannabis pollen, leaves, hemp seeds and/or flower tops.^{9 11–16}

Studies on recreational cannabis allergy put forward different potential allergenic components such as a thaumatin-like protein (TLP),

Key messages

What is already known about this subject?

- Although rare, some anecdotal case reports and small series point to work-related cannabis allergy.
- This study aims at exploring the potential allergic health risks of occupational cannabis exposure.

What are the new findings?

- Respiratory and cutaneous symptoms are common in people with occupational cannabis exposure. However, IgE-mediated allergy for cannabis itself or house dust mites, moulds or pollen does not seem to be the cause.
- The exact reason for these symptoms remains elusive but could probably be non-immune reactions.

How might this impact on policy or clinical practice in the foreseeable future?

- There is a need for much improvement by focusing on protective clothing possibly reducing the number of symptoms reported on duty, independent of their origin.

ribulose-1,5-bisphosphate carboxylase/oxygenase (RuBisCo) and Can s 3 (the non-specific lipid transfer protein (nsLTP)). It is important to note that nsLTPs are also involved in cannabis allergy resulting from mere passive exposure to cannabis smoke and/or indirect cutaneous transmission.¹⁷ Moreover, it has been suggested that recreational cannabis allergy also displays distinct geographically dependent reactivity profiles, with sensitisations to RuBisCo mostly found in USA whereas TLP and Can s 3 sensitisations seem to predominate in Europe.^{3 4 18–21}

A previous report on the safety of Belgian illicit indoor cannabis plantations shows that both growers and intervention staff are faced with serious health risks caused by pesticide use.²² In contrast, little is known about cannabis-associated allergies as a potential occupational health hazard, particularly in people who are involved in the dismantling of plantations on a regular basis. Actually, to the best of our knowledge, no data are available on the prevalence, clinical phenotype or allergenic reactivity profile of these occupationally exposed individuals. Therefore, this study aims to explore the potential allergic health risks of occupational



© Author(s) (or their employer(s)) 2018. No commercial re-use. See rights and permissions. Published by BMJ.

To cite: Decuyper II, Van Gasse A, Faber MA, et al. *Occup Environ Med* Epub ahead of print: [please include Day Month Year]. doi:10.1136/oemed-2018-105302

cannabis exposure in people responsible for the localisation and dismantling of illicit cannabis plantations.

METHODS

Participants

Participants were included in collaboration with the Belgian Federal Police and different local police departments. A research call was sent out through email as well as posters in pre-designated offices. Inclusion criteria were defined as occupational cannabis exposure during the past 12 months with cutaneous contact and/or respiratory (environmental) exposure on entering plantations or during an arrest or seizure of drugs. Individuals using oral antihistamines and/or corticosteroids, and pregnant and lactating women were excluded. Demographics and history were obtained by trained physicians and complemented by a standardised questionnaire which can be found in online supplementary file 1. Patients signed informed consent in accordance with the Declaration of Helsinki.

Skin prick tests

Skin prick tests (SPTs) included inhalant allergens: birch (*Betula verrucosa*), timothy grass (*Phleum pratense*), mugwort (*Artemisia vulgaris*) (HAL, Haarlem, The Netherlands) and an nsLTP-rich extract from cannabis (*C. sativa*) prepared as described elsewhere.³ Skin test responses were read after 15 min and a weal exceeding 3 mm (longest diameter) was considered positive. A positive control with histamine (10 mg/mL) and a negative saline control without allergen (ALK-Abello, Berkshire, UK) were performed to rule out non-responsiveness or dermographism of the skin, respectively.

Total and specific IgE measurement

To identify potential alternative elicitors for symptoms on occupational cannabis exposure, specific IgE (sIgE) was quantified to house dust mite (*Dermatophagoides pteronyssinus*), recombinant (r)Bet v 1 from birch (*B. verrucosa*), sIgE to rPhl p 1 and rPhl p 5b from timothy grass (*P. pratense*) and sIgE to mugwort (*A. vulgaris*). sIgE to rPru p 3 from peach (*Prunus persica*) was quantified as a marker for nsLTP sensitisation and sIgE to three different moulds: *Cladosporium herbarum*, *Penicillium chrysogenum* and *Aspergillus fumigatus* was measured because these species were found most prevalent in illicit cannabis plantations.^{23 24} Finally, total IgE was also quantified. Total and sIgE quantifications relied on the fluorescent enzyme immunoassay (FEIA) ImmunoCAP technique (Phadia Thermo Fisher Scientific) and were carried out according to the manufacturer's instructions. For sIgE, a result >0.10 kU_A/L was considered positive.

Basophil activation test

The basophil activation test (BAT) was performed as described in detail elsewhere.²⁵ Briefly, prewarmed heparinised blood samples were stimulated with 1 µg/mL of recombinant Can s 3 and 0.1 µg/mL of a crude cannabis extract. Preparation of extracts and dose-finding experiments are described elsewhere.^{21 26 27} Anti-human IgE served as a positive control (10 µg/mL, BD Biosciences, Erembodegem, Belgium) to measure cell responsiveness and stimulation buffer was used to measure spontaneous CD63 expression in quiescent cells. Analysis of basophil activation was performed using side scatter, anti-IgE and anti-CD203c to characterise the basophils. Subsequently, within the gate of IgE⁺/CD203c⁺ cells, the percentage of activated basophils, that is, those expressing CD63, was measured. Results were expressed as net percentages of CD63⁺ basophils, calculated by subtraction

of the spontaneous expression from the allergen-induced CD63 expression. 'Responders' were defined as 15% or more CD63 basophils on stimulation with the positive control. Based on our prior validation experiments, CD63 >5% upon allergen stimulation was defined as a positive result.^{21 28}

RESULTS

Study population characteristics

In total, 119 individuals responded to our research call, subsequently 87 individuals were eligible for participation in the study between February and June 2017. However, six did not receive complete diagnostic testing or were not seen by a trained physician and were therefore excluded. Of the 81 remaining participants, one participant was active in the Dutch police force; all others were part of a local or federal unit of the Belgian police force. The median age was 45.0 years (26–60 years) with a male to female ratio of 56:25.

The majority (89%, 72/81) of participants report entering cannabis plantations five times a year or more; 43% (35/81) even report monthly exposure to cannabis. Many (53%, 43/81) are actively involved in the dismantling of plantations with manual removal of the cannabis plants; the remainder enter cannabis plantations to perform forensic research, to make an inventory/supervise dismantling, or are exposed to cannabis during drug arrests and/or at the police academy. Only 3/81 reported asymptomatic recreational use of cannabis dating back more than 12 months. Notwithstanding recommendations, only one participant reported the use of fully protective clothing.

In 17 participants (21%) a pollen allergy was confirmed by a history of seasonal rhinoconjunctivitis combined with a positive SPT for birch, timothy grass or mugwort pollen. Three participants (4%) showed a sensitisation for (at least one of the tested) mould species and 32 participants (40%) exhibited a sensitisation to house dust mite. Nine participants (10%) reported atopic dermatitis (with need for topical corticosteroids in the last 12 months) and 10 participants reported asthma.

Thirty-four participants (42%) reported respiratory and/or cutaneous symptoms (up)on occupational exposure to cannabis. Thirty-three of them (97%) reported these symptoms in relation to entering cannabis plantations, the remainder experienced these symptoms when handling the drug outside of these environments. Eight individuals (10%) reported other symptoms such as headache, tiredness or facial flushing which were not specific for occupational cannabis contact. Twenty individuals reported respiratory symptoms, mainly rhinoconjunctivitis (44%), throat irritation (41%), and over 40% reported mild to moderate dyspnoea. Cutaneous symptoms were reported by eight individuals and mainly comprised local or generalised pruritus and erythema. Six individuals (7%) reported both respiratory and cutaneous symptoms on exposure. When comparing the symptomatic and tolerant participants, the number of participants with asthma or atopic dermatitis did not significantly differ.

Diagnostics

Cannabis sensitisation

As summarised in figure 1, 71 out of 81 participants (88%) were categorised as BAT responders. Thirty of these 71 reported respiratory and/or cutaneous symptoms. In these 71 cases, all BATs for crude cannabis extract and rCan s 3 were negative, except in one symptomatic case who demonstrated an isolated and borderline result of 7% degranulating basophils (CD63 positivity) for rCan s 3. All SPTs with the nsLTP rich cannabis extract yielded negative results.




Figure 1 Cannabis allergy diagnostics. From left to right: basophil activation test (BAT) with rCan s 3 (1 µg/mL) and a crude cannabis extract (0.1 µg/mL) and a skin prick test (SPT) performed with an nCan s 3-rich extract (weal >3 mm defined as a positive result). For both BATs >5% CD63-basophils were defined as a positive result. Responders are defined as ≥15% CD63-basophils after stimulation with anti-IgE; non-responders lack this feature. CS, Cannabis sativa; nsLTP, non-specific lipid transfer protein.

Other allergic sensitisations

To identify potential alternative elicitors for the respiratory and cutaneous symptoms on occupational cannabis exposure, sIgE was quantified to house dust mites, components of different endemic pollen and three different moulds. The results of these quantifications can be found in table 1 and show that there is no significant difference between the numbers of sensitised patients to any of these allergens in the groups with and without respiratory and/or cutaneous symptoms on entering a cannabis plantation. Even when patients without respiratory or cutaneous symptoms are compared with each symptomatic subgroup, for example, patients with respiratory complaints, cutaneous symptoms or both, no significant differences were found.

DISCUSSION

To our knowledge this is the first survey to explore the potential allergy-associated health risks of occupational cannabis

exposure in police forces involved in the dismantling of illegal cannabis plantations and drug arrests. Our study population comprised participants with frequent and strong involvement in the assessment and dismantling of illegal cannabis plantations. The results demonstrate that reported respiratory and cutaneous symptoms on exposure to cannabis are common and occur mostly during or immediately after entering illegal plantations but none of the participants demonstrated an unequivocal genuine cannabis sensitisation or allergy, notwithstanding the use of multiple well-standardised and validated cannabis diagnostics.^{3 21} Actually, all in vitro and in vivo confirmatory tests with crude cannabis extracts and recombinant Can s 3 yielded negative results except in one patient with cutaneous symptoms on entering cannabis plantations who demonstrated an isolated and borderline basophil response to the recombinant nsLTP from cannabis. As these tests are not commercially available, they were specifically manufactured and previously validated to

Table 1 Aeroallergen diagnostics and clinical atopic features

	Respiratory and/or cutaneous symptoms		Respiratory symptoms n=20	Cutaneous symptoms n=8	Respiratory and cutaneous symptoms n=6
	Absent Total n=47	Present Total n=34			
Atopic dermatitis	11% (5/47)	12% (4/34)	15%	0%	17%
Asthma	11% (5/47)	12% (4/34)	15%	13%	50%
Pollen allergy*	15% (7/47)	30% (10/33)	30%	38%	17%
Total IgE†	91.4 (19.7)	93.6 (35.8)	100 (60.4)	68.3 (19.3)	107 (50.7)
sIgE house dust mite	34% (16/47)	48% (16/33)	42% (8/19)	63% (5/8)	50% (3/6)
sIgE rBet v 1	15% (7/47)	18% (6/33)	16% (3/19)	25% (2/8)	17% (1/6)
sIgE rPhl p 1	13% (6/47)	27% (9/33)	32% (6/19)	38% (3/8)	0/6
sIgE rPhl p 5b	6% (3/47)	18% (6/33)	16% (3/19)	38% (3/8)	0/6
sIgE <i>Artemisia vulgaris</i>	4% (2/47)	9% (3/33)	6% (1/18)	25% (2/8)	0/6
sIgE <i>Penicillium chrysogenum</i>	2% (1/47)	0/33	0/18	0/8	0/6
sIgE <i>Cladosporium herbarum</i>	2% (1/47)	0/33	0/18	0/8	0/6
sIgE <i>Aspergillus fumigatus</i>	2% (1/47)	0/33	0/18	0/8	0/6
sIgE rPru p 3	0/47	3% (1/33)	0/18	13% (1/8)	0/6

*Defined as seasonal rhinoconjunctivitis and a positive (>3 mm weal) SPT for birch, timothy grass or mugwort pollen.²

†Expressed as mean (SE). P>0.05 for the comparison of the symptomatic and asymptomatic groups for all of the abovementioned variables.

sIgE, specific IgE; SPT, skin prick test.

detect cannabis allergy.^{3 21} Preliminary dose-response analyses yielded optimal allergen concentrations for the BATs which were confirmed to have good performance in a larger more extensive survey.²⁸ A small number of symptomatic patients in this current study were non-responsive in the BAT and subsequently no firm conclusions can be made about their negative BAT results for both crude cannabis extracts and rCan s 3. However, false-negative results are unlikely because of the negative SPT results, a test known to have good sensitivity.³ Moreover, this study looks beyond cannabis as the cause of the occupational respiratory and/or cutaneous symptoms. As a matter of fact, the prevalence of asthma, atopic dermatitis and other environmental factors that might play a role in cannabis plantations, such as other traditional inhalant allergens (house dust mite, moulds and pollen), were also investigated. From these analyses it appears that the reported symptoms are unlikely to be attributable to asthma or atopic dermatitis, nor to other aeroallergenic causes, as no differences in sensitisations, prevalence of asthma or atopic dermatitis were found between the symptomatic and asymptomatic individuals.

Essentially, our data indicate that the explanation for the occupation-related symptoms in our cases probably lies in alternative, non-immune-mediated mechanisms. Previous studies^{29 30} have found that exposure to microbial contaminants or organic dust in hemp factory workers can attribute to byssinosis, a form of occupational asthma. Therefore, byssinosis could account, to some extent, for the reported respiratory symptoms but not the cutaneous symptoms. In addition, byssinosis is mainly described in outdoor plantations whereas a report of the *Belgian Science Police Office*³¹ mainly speak of busts of indoor plantations in this region. On the other hand, Cuyper *et al*²² recently speculated that various pesticides present in indoor plantations or sprayed on the leaves might lead to mucocutaneous exposure and present a health risk for intervention staff. In addition, the indoor spaces in which cannabis plantations are found are commonly very humid and poorly ventilated. Although these explanations might explain the respiratory symptoms of dyspnoea, cough and even rhinoconjunctivitis, it should be questioned whether both generalised cutaneous and respiratory symptoms, as reported in this study, are likely to be caused solely by irritation. Nevertheless, this study is the first to link these toxicities to actual health problems which makes it impossible to compare these findings to previous research.

LIMITATIONS

Collectively, our data indicate that respiratory and cutaneous symptoms are common following occupational cannabis exposure but do not originate from any of the IgE-mediated allergies tested for. However, a possible limitation of the study is that it was volunteer-based, likely causing a selection bias; people with symptoms on exposure could have been more motivated to participate in this study. Second, a potential criticism on our study could be that the used cannabis allergy diagnostics failed to correctly document occupational cannabis sensitisation. Because unlike recreational cannabis use and because of different exposition route(s), other allergens might predominate in occupational cannabis sensitisation. However, as shown by our data, results obtained with BAT with a crude cannabis extract are entirely comparable with BAT rCan s 3 and SPT with an nsLTP-rich extract. Actually, virtually all symptomatic participants had entirely negative explorations. Third, a recent American study³² reported that the mould *Botrytis cinerea* was found most often in outdoor cannabis plantations. This differs from

the earlier findings^{22 24} concerning moulds in indoor cannabis plantations, mainly in Belgium. Although this discrepancy might result from differences between indoor and outdoor environments or geographical climate differences, it would be interesting to include sIgE to *B. cinerea* in future research. Finally, in future prospective research on occupational cannabis exposure, it might be beneficial to quantify urine tetrahydrocannabinol (THC) levels at the time of exposure. This would help investigate whether this occupational exposure can induce any THC uptake and enable the evaluation of subsequent physiological cannabis effects. As this study was designed to retrospectively query occupational cannabis exposure, information on urine THC levels at the time of exposure was not available.

CONCLUSION

In conclusion, our survey confirms that respiratory and/or cutaneous symptoms are common in people with occupational cannabis exposure. However, IgE-mediated allergy for cannabis, house dust mite, moulds or pollen do not seem to be the causative elicitors. As a matter of fact, the exact reason(s) for these clinical manifestations remain(s) elusive but are likely due to non-immune reactions. As this is the first study to explore allergy-associated risks of occupational cannabis exposure, its findings should be confirmed in larger studies, especially since the overall prevalence of cannabis allergy still remains elusive. A last but important fact to highlight is that only one participant reported use of fully protective gear. This observation suggests that focusing on better availability and use of protective clothing might possibly reduce the number of symptoms reported on duty, independent of their origin.

Acknowledgements The authors thank B Van Camp, head of the Unit 'drug production', Central Drug Department, Directorate of Organized Crime, Belgian Federal judicial police for his help with setting up this project and the communication with the different police departments. The authors also thank K Vandebos and N Maes, their study nurses, for their help in the performance of the skin prick tests and blood sampling. Furthermore, VS is a senior clinical researcher of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1804518N). DE is a senior clinical researcher of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1800614N). AVG is a fellow of the Research Foundation Flanders/Fonds Wetenschappelijk Onderzoek (FWO: 1113617N).

Contributors IID: study set-up, organisation, participant inclusion, data analyses, writing the manuscript. AVG: help in participant inclusion, blood sample collection and performance of skin prick tests. MAF: discussing results, correcting and proof-reading the manuscript. CM: performance of BAT and sIgE measurements, proof-reading manuscript. JE: correcting and proof-reading the manuscript. H-PR: production of Can s 3 protein, discussing results, correcting and proof-reading the manuscript. SV: correcting and proof-reading the manuscript. HL: help with participant inclusion, correcting and proof-reading the manuscript. MH: correcting and proof-reading the manuscript. CB: discussing flow-cytometric analyses, correcting and proof-reading the manuscript. LDC: correcting and proof-reading the manuscript. DE: help with study set-up, discussing results and analyses, writing, correcting and proof-reading the manuscript. IID and DE are guarantors of the paper.

Funding This work was supported by Agentschap voor Innovatie door Wetenschap en Technologie (IWT) (grant number 140185).

Competing interests None declared.

Patient consent Not required.

Ethics approval The local ethics committee of both the University Hospital of Antwerp and of Ghent approved and registered this study (B300201524055).

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- 1 Liskow B, Liss JL, Parker CW. Allergy to marihuana. *Ann Intern Med* 1971;75:571–3.
- 2 Gamboa P, Sanchez-Monge R, Sanz ML, *et al*. Sensitization to Cannabis sativa caused by a novel allergenic lipid transfer protein, Can s 3. *J Allergy Clin Immunol* 2007;120:1459–60.

- 3 Ebo DG, Swerts S, Sabato V, *et al.* New food allergies in a European non-Mediterranean region: is Cannabis sativa to blame? *Int Arch Allergy Immunol* 2013;161:220–8.
- 4 Armentia A, Castrodeza J, Ruiz-Muñoz P, *et al.* Allergic hypersensitivity to cannabis in patients with allergy and illicit drug users. *Allergol Immunopathol* 2011;39:271–9.
- 5 Stadtmayer G, Beyer K, Bardina L, *et al.* Anaphylaxis to ingestion of hempseed (Cannabis sativa). *J Allergy Clin Immunol* 2003;112:216–7.
- 6 de Larramendi CH, Carnés J, García-Abujeta JL, *et al.* Sensitization and allergy to Cannabis sativa leaves in a population of tomato (Lycopersicon esculentum)-sensitized patients. *Int Arch Allergy Immunol* 2008;146:195–202.
- 7 Faber M, Van Gasse A, Sabato V, *et al.* Marihuana allergy: beyond the joint. *J Invest Allergol Clin Immunol* 2015;25:70–2.
- 8 Stöckli SS, Bircher AJ. Generalized pruritus in a patient sensitized to tobacco and cannabis. *J Dtsch Dermatol Ges* 2007;5:303–4.
- 9 Rojas Pérez-Ezquerro P, Sánchez-Morillas L, Davila-Fernandez G, *et al.* Contact urticaria to Cannabis sativa due to a lipid transfer protein (LTP). *Allergol Immunopathol* 2015;43:231–3.
- 10 Spiewak R, Góra A, Dutkiewicz J. Work-related skin symptoms and type I allergy among eastern-Polish farmers growing hops and other crops. *Ann Agric Environ Med* 2001;8:51–6.
- 11 Williams C, Thompson J, Wilkinson M. Work-related contact urticaria to Cannabis sativa. *Contact Dermatitis* 2008;58:62–3.
- 12 Herzinger T, Schöpf P, Przybilla B, *et al.* IgE-mediated hypersensitivity reactions to cannabis in laboratory personnel. *Int Arch Allergy Immunol* 2011;156:423–6.
- 13 Vidal C, Fuente R, Iglesias A, *et al.* Bronchial asthma due to Cannabis sativa seed. *Allergy* 1991;46:647–9.
- 14 Mayoral M, Calderón H, Cano R, *et al.* Allergic rhinoconjunctivitis caused by Cannabis sativa pollen. *J Invest Allergol Clin Immunol* 2008;18:73–4.
- 15 Tesser A, Berlin N, Sussman G, *et al.* Hypersensitivity reactions to marijuana. Annals of allergy, asthma & immunology: official publication of the American College of Allergy, Asthma, & Immunology 2012;108:282–4.
- 16 Majmudar V, Azam NA, Finch T. Contact urticaria to Cannabis sativa. *Contact Dermatitis* 2006;54:127.
- 17 Decuyper II, Faber MA, Sabato V, *et al.* Where there's smoke, there's fire: cannabis allergy through passive exposure. *J Allergy Clin Immunol Pract* 2017;5:864–5.
- 18 Larramendi CH, López-Matas MÁ, Ferrer A, *et al.* Prevalence of sensitization to Cannabis sativa. Lipid-transfer and thaumatin-like proteins are relevant allergens. *Int Arch Allergy Immunol* 2013;162:115–22.
- 19 Rihs HP, Armentia A, Sander I, *et al.* IgE-binding properties of a recombinant lipid transfer protein from Cannabis sativa. *Ann Allergy Asthma Immunol* 2014;113:233–4.
- 20 Nayak AP, Green BJ, Sussman G, *et al.* Characterization of Cannabis sativa allergens. *Ann Allergy Asthma Immunol* 2013;111:32–7.
- 21 Decuyper II, Faber MA, Lapeere H, *et al.* Cannabis allergy: a diagnostic challenge. *Allergy* 2018;73:1911–4.
- 22 Cuypers E, Vanhove W, Gotink J, *et al.* The use of pesticides in Belgian illicit indoor cannabis plantations. *Forensic Sci Int* 2017;277:59–65.
- 23 Martyny JW, Serrano KA, Schaeffer JW, *et al.* Potential exposures associated with indoor marijuana growing operations. *J Occup Environ Hyg* 2013;10:622–39.
- 24 Vanhove W, Cuypers E, Bonneure AJ, *et al.* The health risks of Belgian illicit indoor cannabis plantations. *J Forensic Sci* 2018;63:1783–9.
- 25 Ebo DG, Bridts CH, Hagendorens MM, *et al.* Basophil activation test by flow cytometry: present and future applications in allergology. *Cytometry B Clin Cytom* 2008;74:201–10.
- 26 Rudeschko O, Fahlbusch B, Henzgen M, *et al.* Optimization of apple allergen preparation for in vivo and in vitro diagnostics. *Allergy* 1995;50:262–8.
- 27 Tomassen MM, Barrett DM, van der Valk HC, *et al.* Isolation and characterization of a tomato non-specific lipid transfer protein involved in polygalacturonase-mediated pectin degradation. *J Exp Bot* 2007;58:1151–60.
- 28 Decuyper II, Van Gasse AL, Faber MA, *et al.* Exploring the diagnosis and profile of cannabis allergy. *J Allergy Clin Immunol Pract* 2018;S2213-2198:30594–4.
- 29 Zuskin E, Mustajbegovic J, Schachter EN. Follow-up study of respiratory function in hemp workers. *Am J Ind Med* 1994;26:103–15.
- 30 Er M, Emri SA, Demir AU, *et al.* Byssinosis and COPD rates among factory workers manufacturing hemp and jute. *Int J Occup Med Environ Health* 2016;29:55–68.
- 31 VNS DMF, Ceulen R, Gerbrands S, *et al.* Illegal drug scene in Belgium and the Netherlands: communicating vessels? *Belgian Science Police Office* 2018.
- 32 Green BJ, Couch JR, Lemons AR, *et al.* Microbial hazards during harvesting and processing at an outdoor United States cannabis farm. *J Occup Environ Hyg* 2018;15:430–40.